PRIOR AUTHORIZATION POLICY

POLICY: Multiple Sclerosis – Plegridy™ (peginterferon beta-1a injection [subcutaneous] – Biogen Idec)

TAC APPROVAL DATE: 07/17/2019

OVERVIEW

Plegridy is an interferon beta product indicated for the treatment of relapsing forms of multiple sclerosis (MS) to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease in adults. A polyethylene glycol (PEG) molecule is covalently attached to interferon beta-1a, which increases the mass of Plegridy compared with other unmodified interferon beta-1a products used for MS. Pegylation reduces the renal clearance of Plegridy and shields it from proteolytic degradation. Plegridy has a half-life of approximately 78 hours in patients with MS. The recommended dosage of Plegridy is 125 mcg injected SC every 14 days. Dose titration at treatment initiation is recommended.

Disease Overview

MS is a chronic, inflammatory, demyelinating, autoimmune disease of the central nervous system (CNS) that impacts almost 1,000,000 people in the US. The condition is marked by inflammation and demyelination, as well as degenerative alterations. Patients usually experience relapses and remissions in their neurological symptoms. For most patients, the onset of MS symptoms occurs when patients are 20 to 40 years of age; however, children can get MS and new onset disease can occur in older adults. The MS disease course is heterogeneous but has some patterns. Approximately 85% to 90% of patients have a relapsing pattern at onset. However, this transitions over time in patients who are untreated to a worsening with very few or no relapses or magnetic resonance imaging (MRI) activity (secondary progressive MS). Around 10% to 15% of patients have a steady progression of symptoms over time (primary progressive MS), marked by some clinical manifestations or by MRI activity. Primary progressive MS is generally diagnosed in patients on the upper level of the typical age range (e.g., almost 40 years of age) and the distribution is equivalent among the two genders. Advances in the understanding of the MS disease process, as well as in MRI technology, spurned updated disease course descriptions in 2013, as well as in 2017. The revised disease courses are clinically isolated syndrome, relapsing remitting MS, primary progressive MS, and secondary progressive MS. Clinically isolated syndrome is now more recognized among the course descriptions of MS. It is the first clinical presentation of MS that displays characteristics of inflammatory demyelination that may possibly be MS but has yet to fulfill diagnostic criteria. It is notable that the other MS designations can be further characterized considering whether patients have active disease (or not active), as well as if disease is worsening or stable. Disability in MS is commonly graded on the deterioration of mobility per the Expanded Disability Status Scale (EDSS) an ordinal scale that ranges from 0 to 10, with higher scores indicating greater disability.

Guidelines

In June 2019, a consensus paper was updated by the MS Coalition that discusses the use of disease-modifying therapies in MS. Many options from various disease classes, involving different mechanisms of action and modes of administration, have shown benefits in patients with MS.
POLICY STATEMENT
Prior authorization is recommended for prescription benefit coverage of Plegridy. Because of the specialized skills required for evaluation and diagnosis of patients treated with Plegridy as well as the monitoring required for adverse events and long-term efficacy, approval requires Plegridy to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA
Coverage of Plegridy is recommended in those who meet the following criteria:

FDA-Approved Indication

1. Multiple Sclerosis (MS). Approve for 1 year if the patient meets the following criteria (A and B):
   A) The patient has a relapsing form of multiple sclerosis (MS); AND
   B) The medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis; AND

CONDITIONS NOT RECOMMENDED FOR APPROVAL
Plegridy has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

1. Non-Relapsing Forms of Multiple Sclerosis (MS). Note: An example of a non-relapsing form of MS is primary progressive MS. The efficacy of Plegridy has not been established in patients with MS non-relapsing forms of MS.1

2. Concurrent Use with Other Disease-Modifying Agents Used for Multiple Sclerosis. Note: Examples of disease modifying agents used for multiple sclerosis include Avonex® (interferon beta-1a injection [intramuscular]), Betaseron®/Extavia® (interferon beta-1b injection), Rebif® (interferon beta-1a injection [subcutaneous]), Copaxone®/Glatopa® (glatiramer acetate injection), Aubagio® (teriflunomide tablets), Gilenya® (fingolimod tablets), Mavenclad® (cladribine tablets), Mayzent® (siponimod tablets), Tecfidera® (dimethyl fumarate delayed-release capsules), Ocrevus® (ocrelizumab injection for intravenous use), Tysabri® (natalizumab injection for intravenous administration), and Lemtrada® (alemtuzumab injection for intravenous use).2 These agents are not indicated for use in combination. Additional data are required to determine if use of disease-modifying MS agents in combination is safe provides added efficacy.

3. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES


**HISTORY**

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes</th>
<th>TAC Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy</td>
<td></td>
<td>10/29/2014</td>
</tr>
<tr>
<td>Annual revision</td>
<td>Added Glatopa™ (glatiramer acetate injection for subcutaneous use) and Lemtrada® (alemtuzumab injection for intravenous use) to the list of medications that should not be given concomitantly with Plegridy.</td>
<td>07/01/2015</td>
</tr>
<tr>
<td>Annual revision</td>
<td>Under the “Conditions Not Recommended for Approval” section, added Zinbryta to the list of disease-modifying agents used for MS in which concurrent use with Plegridy is not recommended.</td>
<td>07/27/2016</td>
</tr>
<tr>
<td>Annual revision</td>
<td>Under the “Conditions Not Recommended for Approval” section, added Ocrevus to the list of disease-modifying agents used for MS in which concurrent use with Plegridy is not recommended.</td>
<td>08/02/2017</td>
</tr>
<tr>
<td>Annual revision</td>
<td>Zinbryta was removed from the market. Therefore, Zinbryta was deleted from the list of medications in which Plegridy should not be used with concomitantly.</td>
<td>08/15/2018</td>
</tr>
</tbody>
</table>
| Early annual revision  | The following criteria changes were made:  
  1. **Multiple Sclerosis:** The criteria was changed to require that the patient has a relapsing form of MS. The criteria that previously required the patient have a diagnosis of multiple sclerosis or has experienced an attack and is at risk of MS.  
  2. **Conditions Not Recommended for Approval:** The condition of Non-Relapsing Forms of MS was added as an exclusion. A note is provided that an example of a non-relapsing form is primary progressive MS. Regarding Use with Other Disease-Modifying Agents for MS, the examples are now listed as a note with Mavenclad and Mayzent added. | 07/17/2019        |

TAC – Therapeutic Assessment Committee; MS – Multiple sclerosis.